Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Working Capital Changes: 2013-2025

Historic Other Working Capital Changes for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$23.2 million.

  • Coherus Oncology's Other Working Capital Changes fell 1560.20% to -$23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.5 million, marking a year-over-year decrease of 13.55%. This contributed to the annual value of -$5.5 million for FY2024, which is 66.13% up from last year.
  • Coherus Oncology's Other Working Capital Changes amounted to -$23.2 million in Q3 2025, which was down 544.81% from $5.2 million recorded in Q2 2025.
  • Coherus Oncology's Other Working Capital Changes' 5-year high stood at $19.0 million during Q3 2022, with a 5-year trough of -$23.2 million in Q3 2025.
  • Its 3-year average for Other Working Capital Changes is -$3.1 million, with a median of -$2.1 million in 2023.
  • In the last 5 years, Coherus Oncology's Other Working Capital Changes soared by 1,737.43% in 2022 and then tumbled by 1,560.20% in 2025.
  • Over the past 5 years, Coherus Oncology's Other Working Capital Changes (Quarterly) stood at $761,000 in 2021, then grew by 20.24% to $915,000 in 2022, then crashed by 695.96% to -$5.5 million in 2023, then surged by 102.04% to $111,000 in 2024, then crashed by 1,560.20% to -$23.2 million in 2025.
  • Its last three reported values are -$23.2 million in Q3 2025, $5.2 million for Q2 2025, and $5.3 million during Q1 2025.